彭敏
肿瘤
科副主任，副主任医师，副教授，博士生导师
科副主任，副主任医师，副教授，博士生导师
导师介绍
| 姓名 | 彭敏 |
| 出生年月 | 1981年2月 |
| 单位 | 武汉大学人民医院肿瘤中心 |
| 所属学科 | 临床医学-肿瘤学 |
| 职务、职称及头衔 | 科副主任，主任医师，副教授，博士生导师 |
| mpeng320@whu.edu.cn | |
| 联系方式 | 027-88041911转83521 |
| 研究方向 |
1.肺癌诊疗的基础及临床转化研究 2.肿瘤免疫治疗的基础与临床转化研究 |
| 个人简介 | 主要从事肿瘤的诊治与科研工作，获国家自然科学基金2项、省科技厅及省卫生厅课题2项、武汉市人才项目1项。以第一作者或通讯作者发表论文20余篇，其中SCI论文10余篇。已参与培养硕士生4名，博士生2名。目前正在培养的硕士生7名。 |
| 学术任职与荣誉 |
中国临床肿瘤学会免疫专家委员会委员 中国医促会胸部肿瘤分会委员 中国医药教育学会肺癌医学教育委员会委员 湖北省临床肿瘤学会常务理事 湖北省临床肿瘤学会免疫治疗专家委员会副主任委员兼秘书长 湖北省临床肿瘤学会青年专家委员会副主任委员兼秘书长 湖北省免疫学会肿瘤生物治疗专委会副主任委员 湖北省医学生物免疫学会转化医学委员会副主任委员 《实用肿瘤杂志》通讯编委 |
| 教育履历 |
1999.09-2004.06武汉大学医学院获学士学位 2004.09-2010.06武汉大学医学院获博士学位（中美联合培养） |
| 工作履历 |
2010.07-2014.11武汉大学人民医院肿瘤中心主治医师 2014.12-2017.9武汉大学人民医院肿瘤中心副教授、副主任医师 2017.10-至今 武汉大学人民医院肿瘤中心，东院区肿瘤科副主任 2019.11至今 武汉大学人民医院肿瘤中心，主任医师 |
| 成果获奖 | 《靶向及智能放疗质控体系创新与应用》2020年获湖北省科学技术二等奖 |
| 代表性论著 |
1.Yao
Jin, Aili Tan, Jia Feng, Zexi Xu, Peiwei Wang, Peng Ruan, Ruijun Luo, Yiming
Weng and Min Peng Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy
in Human Cancers: A Systematic Review and Meta-Analysis Front. Oncol., 25
June 2021 2.Xu Zexi, Feng Jia, Weng Yiming, Jin Yao, Peng Min, Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis, J Oncol., 2021, 6631643. 3. Manman Wang, Tan Zhang, Xuechun Zhang, Zhou Jiang, Min Peng and Zan Huang BMP2K dysregulation promotes abnormal megakaryopoiesis in acute megakaryoblastic leukemia Cell Biosci (2020) 10:57 4. Liang Chen, Yi Ming Weng, Meng Xue Hu, Min Peng, Qi Bin Song.Effects of HER2 status on the prognosis of male breast cancer: a population-based study.Onco Targets Ther. 2019; 12: 7251–7260. 5. Gao Z, Peng M, Chen L, Yang X, Li H, Shi R, Wu G, Cai L, Song Q, Li C.Prion Protein Protects Cancer Cells against Endoplasmic Reticulum Stress Induced Apoptosis.Virol Sin. 2019 Apr;34(2):222-234. 6. Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li,Zhongliang Zheng, Bin Xu, Yingge Li ,Yi Dong.Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samplesThoracic Cancer 10 (2019) 193–202 7. Min Peng,Xing Li,Gu Lei,Yi Ming Weng,Meng Xue Hu, Qi Bin Song.The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.2018:11 7369–7383 OncoTargets and Therapy 8. Yi Ming Weng ,Min Peng, Meng Xue Hu, Yi Yao ,Qi Bin Song Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.2018:11 7529–7542,OncoTargets and Therapy 9. Peng M., Weng Y.,Liu H., Yang G., Yao Y.,Han G., Song Q. Clinical characteristics and survival outcomes for non-small cell lung cancer patients with epidermal growth factor receptor double mutations. 2018.Biomed Research International 10. Chen L., Peng M., Li N., Song Q. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in nonsmall cell lung cancer.2018.Scientific Report 11. Peng M., Shi L.,Ke S. Nicotinamide-based diamides derivatives as potential cytotoxic agents: synthesis and biological evaluation.2017. Chemistry Central Journal 11:109. 12. Hu Q, Chu Y, Hu W, Peng M, Song Q.The Cytotoxic Effect of GW843682X on Nasopharyngeal Carcinoma. 2016.Anti-Cancer Agents in Medicinal Chemistry. 16, 1-6. |
| Name | Min Peng |
| Date of birth | Feb.1981 |
| Department | Oncology Department，Renmin Hospital,Wuhan University. |
| Title | Vice Director, Professor, doctoral tutor |
| mpeng320@whu.edu.cn | |
| TEL | 027-88041911-83521 |
| Research Direction |
1.
basis and clinical translation research of lung cancer 2. basis and clinical translation research of immunotherapy |
| Personal Profile | She is mainly engaged in the diagnosis and treatment of Cancer ,and has been awarded 2 items for the National Natural Science Foundation, 2 items from the provincial science and Technology Department and the Provincial Health Department.More than 20 papers published by the first or corresponding author, including 10 SCI papers.By now,she has educated 4 masters and 2 doctors. At present, there are 7 Masters studying with her. |
| Selected Publications |
1.Yao Jin, Aili Tan, Jia Feng, Zexi Xu, Peiwei Wang, Peng Ruan, Ruijun Luo, Yiming Weng and Min Peng Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis Front. Oncol., 25 June 2021 2.Xu Zexi, Feng Jia, Weng Yiming, Jin Yao, Peng Min, Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis, J Oncol., 2021, 6631643. 3. Manman Wang, Tan Zhang, Xuechun Zhang, Zhou Jiang, Min Peng and Zan Huang BMP2K dysregulation promotes abnormal megakaryopoiesis in acute megakaryoblastic leukemia Cell Biosci (2020) 10:57 4. Liang Chen, Yi Ming Weng, Meng Xue Hu, Min Peng, Qi Bin Song.Effects of HER2 status on the prognosis of male breast cancer: a population-based study.Onco Targets Ther. 2019; 12: 7251–7260. 5. Gao Z, Peng M, Chen L, Yang X, Li H, Shi R, Wu G, Cai L, Song Q, Li C.Prion Protein Protects Cancer Cells against Endoplasmic Reticulum Stress Induced Apoptosis.Virol Sin. 2019 Apr;34(2):222-234. 6. Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li,Zhongliang Zheng, Bin Xu, Yingge Li ,Yi Dong.Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samplesThoracic Cancer 10 (2019) 193–202 7. Min Peng,Xing Li,Gu Lei,Yi Ming Weng,Meng Xue Hu, Qi Bin Song.The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.2018:11 7369–7383 OncoTargets and Therapy 8. Yi Ming Weng ,Min Peng, Meng Xue Hu, Yi Yao ,Qi Bin Song Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.2018:11 7529–7542,OncoTargets and Therapy 9. Peng M., Weng Y.,Liu H., Yang G., Yao Y.,Han G., Song Q. Clinical characteristics and survival outcomes for non-small cell lung cancer patients with epidermal growth factor receptor double mutations. 2018.Biomed Research International 10. Chen L., Peng M., Li N., Song Q. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in nonsmall cell lung cancer.2018.Scientific Report 11. Peng M., Shi L.,Ke S. Nicotinamide-based diamides derivatives as potential cytotoxic agents: synthesis and biological evaluation.2017. Chemistry Central Journal 11:109. 12. Hu Q, Chu Y, Hu W, Peng M, Song Q.The Cytotoxic Effect of GW843682X on Nasopharyngeal Carcinoma. 2016.Anti-Cancer Agents in Medicinal Chemistry. 16, 1-6. |
武汉大学人民医院
湖北省人民医院